-
Je něco špatně v tomto záznamu ?
The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin
B. Vraníková, J. Gajdziok, P. Doležel,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- anticholesteremika aplikace a dávkování chemie MeSH
- farmaceutické pomocné látky chemie MeSH
- povidon chemie MeSH
- příprava léků MeSH
- rosuvastatin kalcium aplikace a dávkování chemie MeSH
- rozpustnost MeSH
- silikáty chemie MeSH
- škrob analogy a deriváty chemie MeSH
- sloučeniny hliníku chemie MeSH
- sloučeniny hořčíku chemie MeSH
- tablety chemie MeSH
- uvolňování léčiv MeSH
- Publikační typ
- časopisecké články MeSH
CONTEXT: The preparation of liquisolid systems (LSS) represents a promising method for enhancing a dissolution rate and bioavailability of poorly soluble drugs. The release of the drug from LSS tablets is affected by many factors, including the disintegration time. OBJECTIVE: The evaluation of differences among LSS containing varying amounts and types of commercially used superdisintegrants (Kollidon® CL-F, Vivasol® and Explotab®). MATERIALS AND METHODS: LSS were prepared by spraying rosuvastatin solution onto Neusilin® US2 and further processing into tablets. Varying amounts of superdisintegrants were used and the differences among LSS were evaluated. The multiple scatter plot method was used to visualize the relationships within the obtained data. RESULTS AND DISCUSSION: All disintegrants do not showed negative effect on the flow properties of powder blends. The type and concentration of superdisintegrant had an impact on the disintegration time and dissolution profiles of tablets. Tablets with Explotab® showed the longest disintegration time and the smallest amount of released drug. Fastest disintegration and dissolution rate were observed in tablets containing Kollidon® CL-F (≥2.5% w/w). Also tablets with Vivasol® (2.5-4.0% w/w) showed fast disintegration and complete drug release. CONCLUSION: Kollidon® CL-F and Vivasol® in concentration ≥2.5% are suitable superdisintegrants for LSS with enhanced release of drug.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17014254
- 003
- CZ-PrNML
- 005
- 20181011123626.0
- 007
- ta
- 008
- 170413s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/10837450.2015.1089900 $2 doi
- 035 __
- $a (PubMed)26401959
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vraníková, Barbora, $d 1987- $7 xx0228025 $u Department of Pharmaceutics, Faculty of Pharmacy , University of Veterinary and Pharmaceutical Sciences , Palackeho Trida 1/3 , Brno , Czech Republic.
- 245 14
- $a The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin / $c B. Vraníková, J. Gajdziok, P. Doležel,
- 520 9_
- $a CONTEXT: The preparation of liquisolid systems (LSS) represents a promising method for enhancing a dissolution rate and bioavailability of poorly soluble drugs. The release of the drug from LSS tablets is affected by many factors, including the disintegration time. OBJECTIVE: The evaluation of differences among LSS containing varying amounts and types of commercially used superdisintegrants (Kollidon® CL-F, Vivasol® and Explotab®). MATERIALS AND METHODS: LSS were prepared by spraying rosuvastatin solution onto Neusilin® US2 and further processing into tablets. Varying amounts of superdisintegrants were used and the differences among LSS were evaluated. The multiple scatter plot method was used to visualize the relationships within the obtained data. RESULTS AND DISCUSSION: All disintegrants do not showed negative effect on the flow properties of powder blends. The type and concentration of superdisintegrant had an impact on the disintegration time and dissolution profiles of tablets. Tablets with Explotab® showed the longest disintegration time and the smallest amount of released drug. Fastest disintegration and dissolution rate were observed in tablets containing Kollidon® CL-F (≥2.5% w/w). Also tablets with Vivasol® (2.5-4.0% w/w) showed fast disintegration and complete drug release. CONCLUSION: Kollidon® CL-F and Vivasol® in concentration ≥2.5% are suitable superdisintegrants for LSS with enhanced release of drug.
- 650 _2
- $a sloučeniny hliníku $x chemie $7 D017607
- 650 _2
- $a anticholesteremika $x aplikace a dávkování $x chemie $7 D000924
- 650 _2
- $a příprava léků $7 D004339
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a sloučeniny hořčíku $x chemie $7 D017616
- 650 _2
- $a farmaceutické pomocné látky $x chemie $7 D010592
- 650 _2
- $a povidon $x chemie $7 D011205
- 650 _2
- $a rosuvastatin kalcium $x aplikace a dávkování $x chemie $7 D000068718
- 650 _2
- $a silikáty $x chemie $7 D017640
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a škrob $x analogy a deriváty $x chemie $7 D013213
- 650 _2
- $a tablety $x chemie $7 D013607
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gajdziok, Jan $u a Department of Pharmaceutics, Faculty of Pharmacy , University of Veterinary and Pharmaceutical Sciences , Palackeho Trida 1/3 , Brno , Czech Republic.
- 700 1_
- $a Doležel, Petr $u a Department of Pharmaceutics, Faculty of Pharmacy , University of Veterinary and Pharmaceutical Sciences , Palackeho Trida 1/3 , Brno , Czech Republic.
- 773 0_
- $w MED00004889 $t Pharmaceutical development and technology $x 1097-9867 $g Roč. 22, č. 2 (2017), s. 138-147
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26401959 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20181011124117 $b ABA008
- 999 __
- $a ok $b bmc $g 1200719 $s 975032
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 22 $c 2 $d 138-147 $e 20150924 $i 1097-9867 $m Pharmaceutical development and technology $n Pharm Dev Technol $x MED00004889
- LZP __
- $a Pubmed-20170413